

15-year old girl with APS type IIIc, with post-thymectomy remission– case report.

Artur Bossowski¹, Milena Jamiolkowska¹, Wiesława Furmaniak², Bernard Rees Smith²

¹Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Białystok, Poland;

²FIRS Laboratories, RSR Ltd, Parc Ty Glas Llanishen Cardiff, United Kingdom.

INTRODUCTION AND OBJECTIVES

Autoimmune polyglandular syndromes (APS) is a group of heterogenous conditions characterized by the association of at least two organ-specific disorders, concerning both endocrine and non-endocrine organs. On the basis of the clinical features, they are divided into four main types. Type III is defined as the combination of autoimmune thyroid disease and other autoimmune condition – divided into subtypes A, B and C. Other combinations of autoimmune endocrine diseases are classified as type IV.

We describe a female patient – with the family history of thyroid diseases in her mother (hyperthyroidism) and aunt (hypothyroidism), and Addison’s disease in her grandmother – who has simultaneously developed the symptoms of autoimmune thyroid disease with the clinical picture of hyperthyroidism and myasthenia at the age of 15. The autoimmune thyroid disease (Graves’ disease as indicated in the further laboratory investigation) was recognized about 2 months before myasthenia.



METHODS


Co-existence of those diseases allow us to diagnose APS type IIIc. After a few months we have discovered positive GAD-Ab (whilst blood sugar levels remain normal and without DM symptoms). No evidence of other autoimmune condition was observed.

In this patient the standard GD - tiamazol and propranolol (untill the MG diagnosis) and MG treatment (immunoglobulines, pyridostigmine) was administered. When the CT scan revealed thymus enlargement, thymectomy was performed.


	Symptoms	Test results	
Nov 2014	weight loss, tremor, decreased physical activity tolerance, tachycardia, swallowing difficulties, voice change, irritability, emotional liability,	TSH <0,005 uIU/ml (L) fT3 6,55 pg/ml (H) fT4 2,33 ng/ml (H) ATG (+) TPO (+) TRAb (+)	
Jan 2015	some of the previous symptoms have disappeared new symptoms occurred: ptosis, facial numbness	EMG stimulation test – positive MUSK-Ab (+) AChR-Ab (+) Enlarged tymus discovered in CT-scan	

RESULTS

CT-scan presenting enlarged thymus




Thyroid hormones during the treatment



TSAb – 277 (>150 = positive) TBAb –10 (>30 = positive)

TRAb during the treatment



Other Antibodies

Antibodies	Jan 2015	Nov 2015
GAD Ab - neg	(-)	(+)
IA-2 Ab	(-)	(-)
Insulin Ab	(-)	(-)
ZnT8 Ab	(-)	(-)
21-OH Ab	(-)	(-)
AchR Ab	(+)	(+)

FIRS Laboratories, RSR Ltd, Parc Ty Glas Llanishen Cardiff, United Kingdom

CONCLUSIONS

Co-existence of miasthenia and Grave’s disease caused not only diagnostic difficulties, but also a number of therapeutic implications

After the surgery we observe not only MG remission, but a significant decrease of TRAb as well.

MG therapy (including thymectomy) helped treating co-existent disease allowing to deal with GD only pharmacologically. That indicates the possibility to achieve post-thymectomy remission of not only MG but other APS components.

Our patient’s case confirms that, even in already diagnosed APS, the organ-specific Ab screening can help identify other latent and subclinical autoimmune diseases before patient develops clinical symptoms.

REFERENCES

1. Betterle C., Dal Pra C., Mantero F., Zanchetta R.; Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction; *Endocr. Rev.* 2002;23, 327–364
2. Myasthenia gravis in conjunction with Graves' disease: a diagnostic challenge. Tanwani LK1, Lohano V, Ewart R, Broadstone VL, Mokshagundam SP; *Endocr Pract.* 2001 Jul-Aug;7(4):275-8.
3. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance; Kuniyasu, Jun Shimizu, Fujio Otsuka and Shimon Sakaguchi Misako Itoh, Takeshi Takahashi, Noriko Sakaguchi, Yuhshi; *J Immunol* 1999; 162:5317-5326;

